机器人胰十二指肠切除术国际基准值:多中心基准分析
该国际多中心研究分析了12个中心2020-2023年418例机器人胰十二指肠切除术患者,建立了13项结局参数的基准值。结果显示转换率≤4.3%、输血率≤2.1%、6个月死亡率≤2.2%、主要并发症≤23.2%,肿瘤学结局与开腹手术相当。
要点
- 机器人胰十二指肠切除术的基准值:转换率≤4.3%、6个月死亡率≤2.2%、主要并发症≤23.2%。
- 胰腺导管腺癌淋巴结清扫数目基准为≥20枚,临床相关胰瘘(B/C级)率≤23.6%。
- 术后胰瘘独立预测因素包括胰管直径≤4 mm、抗凝治疗和非PDAC指征。
核心结论
- 研究建立了首个机器人胰十二指肠切除术的国际基准值,显示肿瘤学结局和并发症与开腹手术相当,并具有微创优势。
研究设计与样本
- 国际多中心回顾性分析,纳入2020-2023年连续接受机器人胰十二指肠切除术且随访至少1年的患者,基准队列共418例来自四大洲12个中心。
主要发现
- 基准值:转换率≤4.3%、输血率≤2.1%、6个月死亡率≤2.2%、主要并发症≤23.2%、CCI®≤20.9。
- 临床相关胰瘘(B/C级)率≤23.6%,临床相关出血(B/C级)率≤12.7%。
- 胰腺导管腺癌(n=123)淋巴结清扫数目基准为≥20枚。
- 手术难度越高与总体术后并发症增加相关(R2=0.38,P=0.019),中心病例量越高与胰腺特异性并发症减少相关(R2=0.28,P=0.044)。
- 术后胰瘘独立预测因素包括胰管直径≤4 mm(OR 1.37,95% CI:1.03,1.82)、抗凝治疗(OR 2.45,95% CI:1.47,3.99)和非PDAC指征(OR 2.33,95% CI:1.68,3.27)。
关键数值与推荐
- 基准病例纳入标准:良性或可切除恶性疾病,未接受新辅助治疗,无动脉切除,无严重合并症,无重大腹部手术史。
- 参考中心要求:每年≥15例,在该领域有科研活跃度,并维护前瞻性数据库。
- 共建立13项结局参数的基准值。
临床怎么用
- 可将基准值用于机器人胰十二指肠切除术的质量控制和中心间比较。
- 关注胰管直径≤4 mm、抗凝治疗和非PDAC指征等高危因素以预测术后胰瘘。
- 中心病例量与胰腺特异性并发症减少相关,提示集中化开展可能有益。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To establish international benchmark values for relevant outcome parameters in robotic Whipple. SUMMARY BACKGROUND DATA: For safe adoption of surgical innovation, robust quality control is essential. Benchmarking is a validated tool for assessing surgical performance. Recent international consensus identified establishing benchmark values for robotic Whipple as top priority. METHODS: We analyzed consecutive patients undergoing robotic Whipple between 2020-2023 with a minimum one-year follow-up. Reference centers were required to perform ≥15 cases/year, be scientifically active in the field, and maintain a prospective database. Benchmark criteria included benign or resectable malignant disease without neoadjuvant therapy, arterial resection, major co-morbidities, or significant previous abdominal surgery. Benchmarks were established for 13 outcome parameters. RESULT: The benchmark cohort comprised 418 patients from 12 centers across four continents. Benchmark values were: conversion rate ≤4.3%, transfusion rate ≤2.1%, 6-month mortality ≤2.2%, major complications ≤23.2%, and CCI® ≤20.9. Clinically relevant pancreatic fistula (grade B/C) and hemorrhage (grade B/C) rates were ≤23.6% and ≤12.7%, respectively. For pancreatic ductal adenocarcinoma (n=123), the benchmark for lymph node yield was ≥20. Higher surgical difficulty was associated with increased overall postoperative morbidity (R2=0.38, P=0.019), higher center caseload with reduced pancreas-specific complications (R2=0.28, P=0.044). Independent POPF predictors included duct diameter ≤4 mm (OR 1.37, 95% CI: 1.03, 1.82), anticoagulation (OR 2.45, 95% CI: 1.47, 3.99), and indication other than PDAC (OR 2.33, 95% CI: 1.68, 3.27). CONCLUSIONS: This study establishes the first international benchmarks for robotic Whipple, demonstrating oncologic outcomes and morbidity comparable to open surgery with the benefits of minimally invasive surgery.
引用
- Pfister M, Li Z, Abbassi F, et al. Setting the Standard in Robotic Whipple Surgery: International Multicenter Benchmark Analysis. Ann Surg. 2026. PMID: 41562520. doi:10.1097/SLA.0000000000007014
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。